BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Z, Ha SH, Moon YJ, Hussein UK, Song Y, Kim KM, Park SH, Park HS, Park BH, Ahn AR, Lee SA, Ahn SJ, Kim JR, Jang KY. Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma. J Exp Clin Cancer Res 2020;39:247. [PMID: 33198792 DOI: 10.1186/s13046-020-01759-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Alemi F, Malakoti F, Vaghari-Tabari M, Soleimanpour J, Shabestani N, Sadigh AR, Khelghati N, Asemi Z, Ahmadi Y, Yousefi B. DNA damage response signaling pathways as important targets for combination therapy and chemotherapy sensitization in osteosarcoma. J Cell Physiol 2022. [PMID: 35383920 DOI: 10.1002/jcp.30721] [Reference Citation Analysis]
2 Hussein UK, Ahmed AG, Song Y, Kim KM, Moon YJ, Ahn AR, Park HS, Ahn SJ, Park SH, Kim JR, Jang KY. CK2α/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway. Cells 2021;10:1770. [PMID: 34359939 DOI: 10.3390/cells10071770] [Reference Citation Analysis]
3 Poltronieri P, Celetti A, Palazzo L. Mono(ADP-ribosyl)ation Enzymes and NAD+ Metabolism: A Focus on Diseases and Therapeutic Perspectives. Cells 2021;10:128. [PMID: 33440786 DOI: 10.3390/cells10010128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Fiorentino F, Carafa V, Favale G, Altucci L, Mai A, Rotili D. The Two-Faced Role of SIRT6 in Cancer. Cancers (Basel) 2021;13:1156. [PMID: 33800266 DOI: 10.3390/cancers13051156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Hussein UK, Ahmed AG, Choi WK, Kim KM, Park SH, Park HS, Noh SJ, Lee H, Chung MJ, Moon WS, Kang MJ, Cho DH, Jang KY. SCRIB Is Involved in the Progression of Ovarian Carcinomas in Association with the Factors Linked to Epithelial-to-Mesenchymal Transition and Predicts Shorter Survival of Diagnosed Patients. Biomolecules 2021;11:405. [PMID: 33803371 DOI: 10.3390/biom11030405] [Reference Citation Analysis]
6 Liu X, Wang Z, Liu M, Zhi F, Wang P, Liu X, Yu S, Liu B, Jiang Y, Bu D. Identification of LTF as a Prognostic Biomarker for Osteosarcoma. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/4656661] [Reference Citation Analysis]